Related Experiment Videos
Reverse hydroxamate-based selective TACE inhibitors.
Noriyuki Kamei1, Tomohiro Tanaka, Kentaro Kawai
1Kaken Pharmaceutical Co., Ltd, 14, Shinomiya, Minamikawara-cho, Kyoto, Yamashina-ku 607-8042, Japan.
Bioorganic & Medicinal Chemistry Letters
|May 6, 2004
Summary
New reverse hydroxamate compounds selectively inhibit TNF-alpha converting enzyme (TACE) with high potency and selectivity. Compound 18 shows excellent oral activity in inhibiting lipopolysaccharide-stimulated TNF-alpha production in rats.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Biochemistry
Background:
- Tumor necrosis factor-alpha (TNF-alpha) is a key mediator in inflammatory diseases.
- TNF-alpha converting enzyme (TACE) is a critical target for controlling TNF-alpha production.
- Selective TACE inhibitors are needed to minimize off-target effects.
Purpose of the Study:
- To develop novel reverse hydroxamate-based inhibitors targeting TACE.
- To evaluate the potency and selectivity of these inhibitors against TACE and matrix metalloproteinases (MMPs).
- To assess the in vivo efficacy of a representative compound in an animal model.
Main Methods:
- Synthesis of novel reverse hydroxamate compounds.
- In vitro enzymatic assays to determine TACE and MMP inhibitory activities.
- In vivo study using lipopolysaccharide (LPS)-stimulated rats to measure TNF-alpha production.
Main Results:
- The described reverse hydroxamate compounds exhibit potent TACE inhibitory activity.
- Compounds demonstrate excellent selectivity against a panel of MMPs (MMP-1, 2, 3, 8, 9, 13, 14, and 17).
- Compound 18 showed significant oral inhibitory activity against LPS-stimulated TNF-alpha production in rats.
Conclusions:
- Reverse hydroxamate-based compounds are effective TACE inhibitors with high selectivity.
- Compound 18 represents a promising candidate for further development as an anti-inflammatory therapeutic.
- These findings support the potential of selective TACE inhibition for treating inflammatory conditions.